Relief that's Fast
- Frequently provides relief in 1 week1
- Urine flow improvement seen in as little as 4 Hours2
- 25% reduction in mean total AUA Symptom Score in 4 days, as show in an open-label study*3 Learn more about this trial
Relief that lasts
- Significant reduction in AUA Symptom Scores in a 6-year open-label study†,3,4 Learn more about this trial
Reduction in mean AUA Symptom Score from baseline‡
FLOMAX relieves both the obstructive and irritative symptoms of BPH3,5
- Obstructive: incomplete emptying, intermittency, weak stream, straining
- Irritative: nocturia, frequency, urgency
See data from FLOMAX clinical trials
 |
Learn more about the trusted safety of FLOMAX |
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
* As measured on day 5. Therapy started on the evening of day 1.
† Patients entered into the 4-year open-label extension study with as many as 2 years of prior tamsulosin experience (159 patients were eligible for 6 years of dosing at start of study). The subset of participants that completed 2 years prior to this extension study had more severe symptoms than the majority of patients.
‡ Mean baseline at year 0 measured as 19.8.
1. FLOMAX Prescribing Information, Boehringer Ingelheim Pharmaceuticals, Inc.
2. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998;51:892-900.
3. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
4. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003;170:498-502.
5. American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). Linthicum, Md: American Urological Association Education and Research, Inc; 2003:1-22,1-23,3-51.
